MANGOCEUTICALS, INC. (MGRX): Entry into a Material Definitive Agreement
MANGOCEUTICALS, INC. (MGRX) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 2 ex10-1.htm EX-10.1 Exhibit 10.1 SUBSCRIPTION AGREEMENT IN MANGOCEUTICALS, INC. A. Subscription . This Agreement has been executed by __________________________, a/an ( Individual/Corporation/LLC/Trust/Partnership ) , residing and/or having a principal place of business
How this was made
The 30-second read
Why it matters
A disclosed subscription agreement at a fixed purchase price ($0.32/share) can shift expectations for dilution and cash runway; however, the excerpt lacks the offering size and proceeds, which are key for valuation impact.
Market read
Traders can update financing/dilution models immediately from the disclosed per-share price and structure, but must confirm total raise size to gauge magnitude.
What to watch
Traders will need the missing details (total shares/aggregate gross proceeds, investor count, closing conditions, and stated use of funds) to judge whether the $0.32 price is meaningfully dilutive versus supportive of runway.
Background
The 8-K reports entry into a material definitive agreement and an unregistered sales component (Item 1.01 and Item 3.02), consistent with a Regulation D equity subscription.
Ticker impact
Mangoceuticals disclosed a subscription agreement in an 8-K, selling restricted common shares at a $0.32 purchase price.
Likely modest negative-to-neutral bias from dilution overhang, unless deal size is small or proceeds materially de-risk operations.
The text confirms entry into a material definitive agreement and provides the per-share purchase price, but the excerpt does not state total shares/aggregate proceeds or closing timeline, limiting precision on magnitude.
Market effects
Microcap biotech/pharma issuers may see read-across from financing terms (price, structure) affecting peer dilution expectations.
Limited; primarily impacts US microcap risk appetite and small-cap biotech sentiment.
Low; this is company-specific capital-raise disclosure with no stated cross-border implications in the excerpt.
Counterpoint
If the offering is small and proceeds fund near-term catalysts, the dilution overhang may be outweighed by reduced financing risk.
Key entities
- issuerMangoceuticals, Inc.
Texas corporation filing the 8-K and entering the subscription agreement to sell restricted common stock.
- agreementSubscription Agreement (Exhibit 10.1)
Regulation D “best efforts, no minimum” offering; purchase price set at $0.32 per share.
